Biomimetic Nanocarriers of Pro-Resolving Lipid Mediators for Resolution of Inflammation in Atherosclerosis

被引:3
|
作者
Anghelache, Maria [1 ]
Voicu, Geanina [1 ]
Deleanu, Mariana [2 ]
Turtoi, Mihaela [1 ]
Safciuc, Florentina [1 ]
Anton, Ruxandra [1 ]
Boteanu, Delia [1 ]
Fenyo, Ioana Madalina [3 ]
Manduteanu, Ileana [1 ]
Simionescu, Maya [1 ]
Calin, Manuela [1 ]
机构
[1] Romanian Acad, Inst Cellular Biol & Pathol Nicolae Simionescu, Med & Pharmaceut Bionanotechnol Lab, Bucharest 050568, Romania
[2] Romanian Acad, Inst Cellular Biol & Pathol Nicolae Simionescu, Liquid & Gas Chromatog Lab, Bucharest 050568, Romania
[3] Romanian Acad, Inst Cellular Biol & Pathol Nicolae Simionescu, Gene Regulat & Mol Therapies Lab, Bucharest 050568, Romania
关键词
atherosclerosis; biomimetic nanoparticles; endothelium; inflammation resolution; macrophages; specialized pro-resolving lipid mediators (SPMs); LONG-CHAIN OMEGA-3-FATTY-ACIDS; SMOOTH-MUSCLE-CELLS; ACTIVATED ENDOTHELIUM; NANOPARTICLES; PEPTIDES; METAANALYSIS; EXPRESSION; LIPOSOMES; DELIVERY; SIGNALS;
D O I
10.1002/adhm.202302238
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Atherosclerosis (ATH) is a systemic disease characterized by a chronic inflammatory process and lipid deposition in the arterial walls. The chronic inflammation within ATH lesions results, at least in part, from the failed resolution of inflammation. This process is controlled actively by specialized pro-resolving lipid mediators (SPMs), namely lipoxins, resolvins, protectins, and maresins. Herein, biomimetic nanocarriers are produced comprising a cocktail of SPMs-loaded lipid nanoemulsions (LN) covered with macrophage membranes (Bio-LN/SPMs). Bio-LN/SPMs retain on their surface the macrophage receptors involved in cellular interactions and the "marker of self" CD47, which impede their recognition and uptake by other macrophages. The binding of Bio-LN/SPMs to the surface of endothelial cells (EC) and smooth muscle cells (SMC) is facilitated by the receptors on the macrophage membranes and partly by SPMs receptors. In addition, Bio-LN/SPMs prove functional by reducing monocyte adhesion and transmigration to/through activated EC and by stimulating macrophage phagocytic activity. After intravenous administration, Bio-LN/SPMs accumulate in the aorta of ApoE-deficient mice at the level of atherosclerotic lesions. Also, the safety assessment testing reveals no side effects or immunotoxicity of Bio-LN/SPMs. Thus, the newly developed Bio-LN/SPMs represent a reliable targeted nanomedicine for the resolution of inflammation in atherosclerosis. Biomimetic nanocarriers of specialized pro-resolving lipid mediators (Bio-LN/SPMs) are developed for the inflammation resolution of atherosclerosis. Bio-LN/SPMs bind to endothelial and smooth muscle cells rather than to macrophages, impede monocyte adhesion/transmigration to/through activated endothelial cells, and enhance the phagocytic activity of macrophages. Moreover, they accumulate in the atherosclerotic plaque of ApoE-deficient mice and are safe for in vivo administration.image
引用
收藏
页数:20
相关论文
共 50 条
  • [21] From Inflammation to Resolution: Specialized Pro-resolving Mediators in Posttraumatic Osteoarthritis
    Leite, Chilan B. G.
    Merkely, Gergo
    Charles, Julia F.
    Lattermann, Christian
    CURRENT OSTEOPOROSIS REPORTS, 2023, 21 (06) : 758 - 770
  • [22] Specialized pro-resolving lipid mediators: a key player in resolving inflammation in autoimmune diseases
    Zhang, Qingxiang
    Wang, Ying
    Zhu, Jie
    Zou, Meijuan
    Zhang, Yuxin
    Wu, Hao
    Jin, Tao
    SCIENCE BULLETIN, 2025, 70 (05) : 778 - 794
  • [23] Pro-resolving lipid mediators in vascular disease
    Conte, Michael S.
    Desai, Tejal A.
    Wu, Bian
    Schaller, Melinda
    Werlin, Evan
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (09): : 3727 - 3735
  • [24] Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma
    Kytikova, Oxana
    Novgorodtseva, Tatyana
    Denisenko, Yulia
    Antonyuk, Marina
    Gvozdenko, Tatyana
    MEDICINA-LITHUANIA, 2019, 55 (06):
  • [25] Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation
    Perretti, Mauro
    Dalli, Jesmond
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2023, 63 : 449 - 469
  • [26] CRITICAL ROLE OF SPECIALIZED PRO-RESOLVING MEDIATORS IN ATHEROSCLEROSIS
    Rangarajan, S.
    Rangchaikul, P.
    Radwan, M. M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (01) : 120 - 120
  • [27] The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis
    Torres, Wheeler
    Perez, Jose Luis
    Diaz, Maria P.
    D'Marco, Luis
    Checa-Ros, Ana
    Carrasquero, Ruben
    Angarita, Lisse
    Gomez, Yosselin
    Chacin, Maricarmen
    Ramirez, Paola
    Villasmil, Nelson
    Duran-Aguero, Samuel
    Cano, Climaco
    Bermudez, Valmore
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [28] Respiratory viral infection and resolution of inflammation: Roles for specialized pro-resolving mediators
    Tavares, Luciana P.
    Nijmeh, Julie
    Levy, Bruce D.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 248 (19) : 1635 - 1644
  • [29] Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases
    Satish, Mohan
    Agrawal, Devendra K.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (03) : 177 - 184
  • [30] Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention
    Dalli, Jesmond
    Kitch, Douglas
    Brien, Meagan P.
    Hunt, Peter W.
    Funderburg, Nicholas
    Moisi, Daniela
    Gupta, Amita
    Brown, Todd T.
    Tien, Phyllis C.
    Aberg, Judith A.
    Shivakoti, Rupak
    EBIOMEDICINE, 2023, 89